The research in our team is focused on the development of novel treatment strategies to target prostate and pancreatic cancers using genetically modified viruses that target, replicate and kill cancer cells but leave normal cells unharmed.
Our lab aims to improve treatments for women with ovarian cancer, particularly those that are resistant to chemotherapy. We are interested in developing therapies that can adapt to the evolution of chemotherapy resistance over time.
Our research focuses on the use of modified, replicating oncolytic Vaccinia viruses and adenoviruses armed with immune-modulatory genes such as cytokines to create a self-propagating treatment for tumours that results in long-term immunological memory to the tumour cells.
My work focuses on cancer immunotherapy using oncolytic viruses (vaccinia virus and adenovirus) and engineered T cells. I will also be looking at the state of immune cells in the tumour microenvironment.